Eric A Storch Selected Research

Cycloserine (Seromycin)

1/2022	Efficacy of D-cycloserine augmented brief intensive cognitive-behavioural therapy for paediatric obsessive-compulsive disorder: A randomised clinical trial.
12/2019	Changes in Dosing and Dose Timing of D-Cycloserine Explain Its Apparent Declining Efficacy for Augmenting Exposure Therapy for Anxiety-related Disorders: An Individual Participant-data Meta-analysis.
1/2018	D-cycloserine-augmented one-session treatment of specific phobias in children and adolescents.
1/2017	A Meta-Analysis of D-Cycloserine in Exposure-Based Treatment: Moderators of Treatment Efficacy, Response, and Diagnostic Remission.
1/2017	D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders: A Systematic Review and Meta-analysis of Individual Participant Data.
8/2016	Efficacy of Augmentation of Cognitive Behavior Therapy With Weight-Adjusted d-Cycloserine vs Placebo in Pediatric Obsessive-Compulsive Disorder: A Randomized Clinical Trial.
7/2014	Does d-Cycloserine Augmentation of CBT Improve Therapeutic Homework Compliance for Pediatric Obsessive-Compulsive Disorder?
8/2013	Difficult-to-treat pediatric obsessive-compulsive disorder: feasibility and preliminary results of a randomized pilot trial of D-cycloserine-augmented behavior therapy.
12/2010	A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder.
7/2007	D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Eric A Storch Research Topics

Disease

50	Obsessive-Compulsive Disorder (Disorder, Obsessive-Compulsive) 01/2022 - 01/2006
10	Anxiety Disorders (Anxiety Disorder) 01/2021 - 04/2008
7	Tics (Tic) 09/2017 - 08/2006
5	Mental Disorders (Mental Disorder) 01/2022 - 01/2019
5	Tic Disorders (Tic Disorder) 07/2017 - 08/2009
4	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 01/2020 - 08/2014
3	Major Depressive Disorder (Major Depressive Disorders) 10/2021 - 04/2008
3	COVID-19 01/2021 - 11/2020
3	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 01/2017 - 08/2009
2	Dystonia (Limb Dystonia) 12/2021 - 10/2020
2	Mood Disorders (Mood Disorder) 10/2021 - 07/2017
2	Social Phobia 01/2021 - 08/2014
2	Trichotillomania 01/2020 - 11/2014
2	Phobic Disorders (Phobia) 01/2018 - 08/2014
2	Pediatric acute-onset neuropsychiatric syndrome 09/2017 - 05/2015
2	Psychomotor Agitation (Akathisia) 12/2015 - 02/2010
2	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 06/2011 - 08/2008
1	Bipolar Disorder (Manic Depressive Psychosis) 10/2021
1	Parkinson Disease (Parkinson's Disease) 01/2021
1	Alzheimer Disease (Alzheimer's Disease) 01/2021
1	Pain (Aches) 12/2018
1	olfactory reference syndrome 10/2018
1	Feeding and Eating Disorders (Eating Disorder) 01/2017
1	Body Dysmorphic Disorders (Body Dysmorphic Disorder) 01/2017
1	Excoriation Disorder 07/2016
1	Tourette Syndrome (Tourette's Syndrome) 05/2016
1	Wounds and Injuries (Trauma) 01/2016
1	Mania (Manias) 12/2015
1	Infections 02/2015
1	Syndrome (Syndromes) 02/2015
1	Panic Disorder (Panic Attack) 08/2014
1	Pharyngitis (Sore Throat) 08/2013
1	Weight Gain 06/2013
1	Streptococcal Infections (Streptococcal Infection) 02/2012

Drug/Important Bio-Agent (IBA)

12	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA 01/2018 - 08/2006
10	Cycloserine (Seromycin)FDA Link 01/2022 - 07/2007
7	Antidepressive Agents (Antidepressants)IBA 01/2022 - 08/2006
4	Biomarkers (Surrogate Marker)IBA 12/2021 - 01/2019
3	Sertraline (Zoloft)FDA LinkGeneric 01/2020 - 01/2008
2	Ketamine FDA LinkGeneric 10/2021 - 01/2020
2	Anti-Bacterial Agents (Antibiotics)IBA 05/2015 - 02/2012
2	beta-cyclodextrin tetradecasulfate (CTDS)IBA 02/2015 - 01/2011
2	Antipsychotic Agents (Antipsychotics)IBA 04/2014 - 08/2006
2	AntibodiesIBA 08/2013 - 02/2012
2	Aripiprazole (Abilify)FDA Link 08/2009 - 01/2008
1	A-factor (Streptomyces)IBA 02/2021
1	trans-sodium crocetinate (crocetin)IBA 01/2020
1	salicylhydroxamic acid (SHAM)IBA 01/2019
1	BuffersIBA 12/2018
1	ORALIT (ORS)IBA 10/2018
1	Azithromycin (Zithromax)FDA LinkGeneric 09/2017
1	tyramine-deoxysorbitolIBA 07/2017
1	7,7'- dimethoxy- (4,4'- bi- 1,3- benzodioxole)- 5,5'- dicarboxylic acid dimethyl ester (BDD)IBA 01/2017
1	dixanthogen (EXD)IBA 07/2016
1	Cefdinir (Omnicef)FDA LinkGeneric 02/2015
1	CytokinesIBA 02/2015
1	Nootropic Agents (Nootropics)IBA 08/2014
1	Paliperidone Palmitate FDA Link 06/2013
1	Complement System Proteins (Complement)IBA 12/2010
1	Hemoglobin AIBA 08/2008
1	Risperidone (Risperdal Consta)FDA LinkGeneric 08/2006
1	Fluoxetine (Prozac)FDA LinkGeneric 01/2006

Therapy/Procedure

15	Therapeutics 01/2022 - 08/2006
11	Deep Brain Stimulation 12/2021 - 05/2016
6	Drug Therapy (Chemotherapy) 01/2021 - 04/2006
5	Transcranial Magnetic Stimulation 01/2022 - 01/2019
4	Combined Modality Therapy 01/2021 - 01/2014
2	Tonsillectomy 08/2013 - 02/2012
2	Adenoidectomy 08/2013 - 02/2012
2	Glycemic Control 06/2011 - 08/2008
1	Medical Day Care (Partial Hospitalization) 01/2022
1	Length of Stay 10/2019
1	Ambulatory Care (Outpatient Care) 01/2018